Correspondence 0001493152-24-005520 from RetinalGenix Technologies Inc. (RTGN) (CIK 0001836295) (RTGN)
RetinalGenix Technologies Inc. (RTGN) (CIK 0001836295)
Date: Feb. 8, 2024 · CIK: 0001836295 · Accession: 0001493152-24-005520
AI Filing Summary & Sentiment
File numbers found in text: 333-262282
Letter
VIA EDGAR United States Securities Division of Corporation Finance Retinalgenix Technologies, Inc. Registration Statement on Form S-1, as amended Filed December 29, 2023 File No: 333-262282
Re:
Dear Sir or Madam:
Retinalgenix Technologies, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-262282), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Monday, February 12, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow and/or Hank Gracin of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238, or Mr. Gracin at (561) 926-7995 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very
truly yours,
RETINALGENIX
TECHNOLOGIES, INC.
Show Raw Text
CORRESP
1
filename1.htm
February
8, 2024
VIA
EDGAR
United
States Securities
and
Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Re:
Retinalgenix
Technologies, Inc.
Registration
Statement on Form S-1, as amended
Filed
December 29, 2023
File
No: 333-262282
Dear
Sir or Madam:
Retinalgenix
Technologies, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration
Statement on Form S-1, as amended (File No. 333-262282), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”)
to become effective on Monday, February 12, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The
Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware
of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration
Statement.
The
Registrant hereby authorizes Leslie Marlow and/or Hank Gracin of Blank Rome LLP to orally modify or withdraw this request for acceleration.
Please contact Ms. Marlow at (516) 457-4238, or Mr. Gracin at (561) 926-7995 with any questions you may have concerning this request,
and please notify either of them when this request for acceleration has been granted.
Very
truly yours,
RETINALGENIX
TECHNOLOGIES, INC.
By:
/s/
Jerry Katzman
Name:
Jerry
Katzman
Title:
Chief
Executive Officer
cc:
Leslie
Marlow, Blank Rome LLP
Hank
Gracin, Blank Rome LLP